Neoadjuvant immunotherapy for Merkel cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 clinical trial investigates the effectiveness of neoadjuvant dual immunotherapy using nivolumab and relatlimab in patients with resectable Merkel cell carcinoma. The study aims to improve recurrence-free survival by targeting PD-1 and LAG-3 immune checkpoint pathways. Participants will receive a fixed dose combination of nivolumab and relatlimab prior to surgical resection, with the hypothesis that this approach will yield a higher pathological response rate compared to previous monotherapy treatments. The trial is conducted at a single center and includes treatment-naïve patients with specific staging criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged ≥ 18 years
2. Written consent
3. Histologically confirmed, resectable Merkel cell carcinoma with AJCC (8th ed) clinical or pathological stage I (≥ 10 mm), IIA, or IIB or III disease
4. In-transit metastases are permitted if they are completely resectable
5. Measurable disease according to RECIST 1.1 criteria
6. Previous radiotherapy permitted if there is RECIST-measurable progression of disease since the completion of radiotherapy
7. At least one of either, archival tissue from a primary or nodal MCC lesion (if applicable) for the current diagnosis and/or a newly obtained core biopsy of a lesion which has not been previously irradiated.
8. ECOG 0-1
9. Adequate organ function on blood pathology
10. Life expectancy \>12 months
11. Female patients to use effective contraception during study treatment and for 5 months after last dose.

Exclusion Criteria:

1. Clinical, radiographic or pathological evidence of distant metastases
2. Contraindication to nivolumab and / or relatlimab
3. Prior anti-PD-1, CTLA-4, PDL-1 or LAG 3 antibody exposure, or an agent directed to another stimulatory or co-inhibitory T-cell receptor for any disease or any chemotherapy or experimental local or systemic drug treatment
4. Active autoimmune disease or requirement for chronic steroid therapy other than hormone replacement therapy
5. A diagnosis of immunodeficiency or chronic steroid therapy \>10 mg OD prednisone or equivalent
6. Additional malignancy active within past 3 years; patients with chronic lymphocytic leukaemia can be included in this study.
7. Uncontrolled cardiovascular disease or history of myocarditis
8. Has had an allogenic tissue/solid organ transplant
9. Troponin T (TnT) or I (TnI) \>2 × institutional ULN
10. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis or current interstitial lung disease
11. Has an active infection requiring systemic therapy
12. Active Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection.
13. Known HIV
14. Pregnant or breast feeding females
15. Concurrent medical or social conditions that may prevent the patient attending assessments or procedures per schedule

Where it's running

• Melanoma Institute Australia
  Wollstonecraft, New South Wales, Australia Recruiting

Study contacts

• Principal investigator: Georgina V Long — Melanoma Instiute Australia
• Study coordinator: Monica Osorio
• Email: monica.osorio@melanoma.org.au
• Phone: + 61 2 9911 7296

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using ctDNA to decide whether to add ipilimumab for people on nivolumab and relatlimab

  This tests whether using a ctDNA blood test to guide adding ipilimumab for adults with advanced or metastatic melanoma on nivolumab and relatlimab leads to longer progression-free survival.

  Recruiting Phase 2 NYU Langone Health · New York, New York · NCT07504796

• HEPZATO KIT with Opdualag for metastatic melanoma that has spread to the liver

  This will try adding HEPZATO KIT to Opdualag (nivolumab + relatlimab) to see if it's safe and helps people with metastatic melanoma that has spread to the liver.

  Recruiting Phase 1/2 University of Wisconsin, Madison · Madison, Wisconsin · NCT07281924

• Comparing two immunotherapy combinations and their immune effects in unresectable or metastatic melanoma

  This will test whether two different first-line immunotherapy combinations produce different immune responses in tumors and blood of people with unresectable or metastatic melanoma.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07223411

• Neoadjuvant ipilimumab, relatlimab, and nivolumab combinations for resectable cutaneous and mucosal melanoma

  This phase 2 trial will test several immunotherapy combinations given before surgery to try to reduce recurrence in adults with resectable stage 3 cutaneous melanoma or resectable mucosal melanoma, including patients predicted or known to respond poorly to standard anti‑PD‑1 therapy.

  Recruiting Phase 2 Melanoma Institute Australia · Wollstonecraft, New South Wales · NCT06999980

• Sacituzumab govitecan with nivolumab, with or without relatlimab, for metastatic triple-negative breast cancer

  This trial tests whether adding nivolumab alone or nivolumab plus relatlimab to sacituzumab govitecan helps people with metastatic triple-negative breast cancer who have had one prior line of chemotherapy.

  Recruiting Phase 1/2 Yale University · New Haven, Connecticut · NCT06963905

• Nivolumab with or without relatlimab for newly diagnosed IDH‑wildtype glioblastoma

  This trial will test whether giving nivolumab alone or together with relatlimab around surgery helps adults with newly diagnosed IDH‑wildtype glioblastoma.

  Recruiting at 4 sites Phase 2 Duke University · New York, New York and 3 other locations · NCT06816927

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.